Werner Kalow
#95,215
Most Influential Person Now
Werner Kalow's AcademicInfluence.com Rankings
Werner Kalowmedical Degrees
Medical
#1029
World Rank
#1323
Historical Rank
Pharmacology
#74
World Rank
#97
Historical Rank
Werner Kalowphilosophy Degrees
Philosophy
#3594
World Rank
#5773
Historical Rank
Logic
#1262
World Rank
#1965
Historical Rank
Download Badge
Medical Philosophy
Why Is Werner Kalow Influential?
(Suggest an Edit or Addition)Werner Kalow's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Intramuscular desferrioxamine in patients with Alzheimer's disease (1991) (685)
- Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine. (1989) (461)
- Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. (2000) (408)
- A METHOD FOR THE DETECTION OF ATYPICAL FORMS OF HUMAN SERUM CHOLINESTERASE. DETERMINATION OF DIBUCAINE NUMBERS (1957) (390)
- Malignant hyperthermia: A statistical review (1970) (385)
- Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity. (1986) (355)
- Metabolic error of muscle metabolism after recovery from malignant hyperthermia. (1970) (307)
- Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1. (1992) (305)
- Hypothesis: comparisons of inter- and intra-individual variations can substitute for twin studies in drug research. (1998) (298)
- On distribution and inheritance of atypical forms of human serum cholinesterase, as indicated by dibucaine numbers. (1957) (290)
- The use of caffeine for enzyme assays: A critical appraisal (1993) (288)
- Variability in caffeine metabolism (1983) (283)
- Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities (1991) (273)
- Cocaine metabolism: Cocaine and norcocaine hydrolysis by liver and serum esterases (1979) (258)
- A comparison of optical and manometric methods for the assay of human serum cholinesterase. (1955) (253)
- Pharmacogenetics of drug metabolism (1980) (252)
- Metabolism of cocaine in man (1978) (245)
- Ethnic Differences in Drug Metabolism (1982) (244)
- Serotonin Subtype 2 Receptor Genes and Clinical Response to Clozapine in Schizophrenia Patients (1998) (233)
- Hydrolysis of cocaine in human plasma by cholinesterase. (1977) (229)
- A simple test for acetylator phenotype using caffeine. (1984) (225)
- Biotransformation of caffeine, paraxanthine, theophylline, and theobromine by polycyclic aromatic hydrocarbon-inducible cytochrome(s) P-450 in human liver microsomes. (1987) (217)
- A method for the detection of atypical forms of human serum cholinesterase; determination of dibucaine numbers. (1973) (217)
- A urinary metabolite ratio that reflects systemic caffeine clearance (1987) (216)
- The dopamine transporter and cytochrome P45OIID1 (debrisoquine 4-hydroxylase) in brain: resolution and identification of two distinct [3H]GBR-12935 binding proteins. (1990) (207)
- Competitive inhibition of sparteine oxidation in human liver by beta-adrenoceptor antagonists and other cardiovascular drugs. (1984) (191)
- Interactions of amphetamine analogs with human liver CYP2D6. (1997) (190)
- In vitro inhibition studies of two isozymes of human liver cytochrome P-450. Mephenytoin p-hydroxylase and sparteine monooxygenase. (1985) (187)
- A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia (2000) (172)
- cDNA cloning and sequence and cDNA-directed expression of human P450 IIB1: identification of a normal and two variant cDNAs derived from the CYP2B locus on chromosome 19 and differential expression of the IIB mRNAs in human liver. (1989) (166)
- Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotype. (1991) (149)
- Hereditary aspects of malignant hyperthermia (1969) (145)
- Pharmacogenetics : heredity and the response to drugs (1962) (141)
- The plasma cholinesteerases: a new perspective. (1981) (141)
- Respiratory and circulatory reflexes from the perfused heart and pulmonary circulation of the dog. (1951) (139)
- The relation between dose of succinylcholine and duration of apnea in man. (1957) (138)
- Genetic polymorphism of mephenytoin p(4')-hydroxylation: difference between Orientals and Caucasians. (1985) (133)
- SOME STATISTICAL DATA ON ATYPICAL CHOLINESTERASE OF HUMAN SERUM (1959) (133)
- The activity of various esterase inhibitors towards atypical human serum cholinesterase (1959) (132)
- Hydrolysis of local anesthetics by human serum cholinesterase. (1952) (128)
- Neuronal cytochrome P450IID1 (debrisoquine/sparteine-type): potent inhibition of activity by (-)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6. (1991) (127)
- Interethnic variation of drug metabolism. (1991) (124)
- Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition. (1995) (120)
- Pharmacogenetics and pharmacogenomics: origin, status, and the hope for personalized medicine (2006) (116)
- Caffeine as a metabolic probe: Validation of its use for acetylator phenotyping (1991) (111)
- THE DISTRIBUTION, DESTRUCTION AND ELIMINATION OF MUSCLE RELAXANTS (1959) (110)
- Polymorphic N‐acetylation of a caffeine metabolite (1983) (110)
- Oxidation of reduced haloperidol to haloperidol: involvement of human P450IID6 (sparteine/debrisoquine monooxygenase). (1991) (107)
- Malignant hyperthermia: an investigation of five patients (1973) (105)
- Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone. (1993) (105)
- Treatment-Resistance to Clozapine in Association With Ultrarapid CYP1A2 Activity and the C → A Polymorphism in Intron 1 of the CYP1A2 Gene: Effect of Grapefruit Juice and Low-Dose Fluvoxamine (2001) (103)
- The caffeine test of isolated human muscle in relation to malignant hyperthermia (1977) (101)
- Sparteine metabolism in Canadian Caucasians (1982) (85)
- Distinction of CYP1A1 and CYP1A2 activity by selective inhibition using fluvoxamine and isosafrole. (1997) (83)
- Malignant hyperthermia: Aetiology unknown (1970) (81)
- Caffeine as a probe for CYP1A2 activity: potential influence of renal factors on urinary phenotypic trait measurements. (1994) (81)
- Biotransformation of caffeine by microsomes from human liver. Kinetics and inhibition studies. (1987) (81)
- Interethnic factors affecting drug response (1994) (81)
- CYP1A2 Activity as Measured by a Caffeine Test Predicts Clozapine and Active Metabolite Norclozapine Steady-State Concentration in Patients With Schizophrenia (2001) (80)
- Paroxetine potentiates the central nervous system side effects of perphenazine: Contribution of cytochrome P4502D6 inhibition in vivo (1997) (79)
- The action of normal and atypical cholinesterase of human serum upon a series of esters of choline. (1960) (75)
- Antipyrine metabolism in the rat by three hepatic monooxygenases. (1980) (74)
- Pharmacogenetics in biological perspective. (1997) (71)
- Deficient metabolism of debrisoquine and sparteine (1980) (70)
- Variability of acetaminophen metabolism in Caucasians and Orientals. (1992) (70)
- Effects of route of administration on dextromethorphan pharmacokinetics and behavioral response in the rat. (1995) (64)
- Variability of caffeine metabolism in humans. (1985) (62)
- Inhibition of sparteine oxidation in human liver by tricyclic antidepressants and other drugs. (1983) (62)
- Interindividual variability in the glucuronidation of (S) oxazepam contrasted with that of (R) oxazepam. (1995) (62)
- Isolation and identification of 5-acetylamino-6-formylamino-3-methyluracil as a major metabolite of caffeine in man. (1983) (61)
- Effect of allopurinol on caffeine disposition in man. (1986) (60)
- Comparative drug elimination capacity in man‐glutethimide, amobarbital, antipyrine, and sulfinpyrazone (1973) (60)
- Metabolic fate of phenobarbital in man. N-Glucoside formation. (1979) (59)
- Genetic study of amobarbital elimination based on its kinetics in twins (1976) (58)
- International Symposium on Malignant Hyperthermia (1973) (56)
- Mephenytoin and sparteine pharmacogenetics in Canadian Caucasians (1984) (56)
- An alternative test for acetylator phenotyping with caffeine (1987) (55)
- Variable activation of lovastatin by hydrolytic enzymes in human plasma and liver (2004) (55)
- Thiopurine S‐methyltransferase activity in a Chinese population (1993) (53)
- Ethnic difference in drug metabolism: debrisoquine 4-hydroxylation in Caucasians and Orientals. (1980) (53)
- Pharmacogenetics and evolution (2000) (53)
- The caffeine breath test and caffeine urinary metabolite ratios in the Michigan cohort exposed to polybrominated biphenyls: a preliminary study. (1990) (52)
- Salivary excretion of amobarbital in man (1975) (50)
- Properties and classification of the soluble esterases of human liver. (1962) (50)
- Pharmacogenetics: Past and future (1990) (50)
- Comparative pharmacogenetics of sparteine and debrisoquine (1983) (49)
- Pharmacogenetics and personalised medicine (2002) (48)
- Epidemiology and inheritance of malignant hyperthermia. (1979) (47)
- Repeat Administration of Drugs as a Means to Assess the Genetic Component in Pharmacological Variability (1999) (46)
- A method for studying drug metabolism in populations: Racial differences in amobarbital metabolism (1979) (42)
- In vitro metabolism of sparteine by human liver: competitive inhibition by debrisoquine. (1982) (41)
- What Will Be the Role of Pharmacogenetics in Evaluating Drug Safety and Minimising Adverse Effects? (2001) (39)
- Pharmacogenetics and Anesthesia (1964) (39)
- Second-Generation Toxicity of Malathion in Rats (1961) (39)
- Metabolism of diazepam in vitro by human liver. Independent variability of N-demethylation and C3-hydroxylation. (1988) (38)
- Family studies of mephenytoin hydroxylation deficiency. (1986) (38)
- CYP2D6 genotype in relation to perphenazine concentration and pituitary pharmacodynamic tissue sensitivity in Asians: CYP2D6–serotonin–dopamine crosstalk revisited (2007) (38)
- CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine (2007) (37)
- Kinetic studies on the hydrolysis of benzoylcholine by human serum cholinesterase. (1956) (37)
- Amobarbital—a probe of hepatic drug oxidation in man (1976) (37)
- Modeling of human hepatic CYP3A4 enzyme kinetics, protein, and mRNA indicates deviation from log-normal distribution in CYP3A4 gene expression (2002) (37)
- Human pharmacogenomics: The development of a science (2004) (37)
- Comparison of effects of several inhalation anaesthetics on caffeine-induced contractures of normal and malignant hyperthermic skeletal muscle (1980) (37)
- Determination of acetylated caffeine metabolites by high-performance exclusion chromatography (1986) (36)
- A human cytochrome P-450 characterized by inhibition studies as the sparteine-debrisoquine monooxygenase. (1984) (36)
- Pharmacogenetics: Its biologic roots and the medical challenge (1993) (36)
- Debrisoquine hydroxylation capacity: Problems of assessment in two populations (1981) (36)
- Contribution of hereditary factors to the response to drugs. (1965) (36)
- Why are diazepam metabolism and polymorphic S‐mephenytoin hydroxylation associated with each other in white and Korean populations but not in Chinese populations? (1993) (35)
- N-Demethylation of cocaine in the rat and in isolated rat hepatocytes: comparison with aminopyrine demethylation. (1978) (34)
- Pharmacogenetics, pharmacogenomics, and pharmacobiology (2001) (34)
- (S)oxazepam glucuronidation is inhibited by ketoprofen and other substrates of UGT2B7. (1995) (33)
- THE "SILENT" GENE FOR SERUM CHOLINESTERASE. (1964) (33)
- A case of deficiency of N‐hydroxylation of amobarbital (1977) (32)
- Haloperidol reduction can be assayed in human red blood cells. (1989) (31)
- Evidence in humans for variant allozymes of the nondeficient sparteine/debrisoquine monooxygenase (P45OIID 1) in vitro. (1989) (31)
- The influence of pH on the ionization and biological activity of d-tubocurarine. (1954) (30)
- The extent and determinants of changes in CYP2D6 and CYP1A2 activities with therapeutic doses of sertraline. (1998) (30)
- Paroxetine steady-state plasma concentration in relation to CYP2D6 genotype in extensive metabolizers. (1999) (30)
- PROPERTIES AND CLASSIFICATION OF THE SOLUBLE ESTERASES OF HUMAN SKELETAL AND SMOOTH MUSCLE. (1965) (30)
- Multigenic control of drug response and regulatory decision-making in pharmacogenomics: The need for an upper-bound estimate of genetic contributions (2005) (29)
- Genetics of drug transformation. (1986) (29)
- Determinants of interindividual variability and extent of CYP2D6 and CYP1A2 inhibition by paroxetine and fluvoxamine in vivo. (1998) (29)
- N-hydroxyamobarbital: the second major metabolite of amobarbital in man. (1975) (29)
- Some properties of the soluble esterases of human liver. (1961) (28)
- The genetic defect of mephenytoin hydroxylation. (1986) (28)
- The Upjohn Award Lecture 1981/La Conférence Upjohn 1981. The metabolism of xenobiotics in different populations. (1982) (28)
- GENETIC FACTORS IN RELATION TO DRUGS. (1965) (28)
- CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentrationin patients with schizophrenia. (2001) (27)
- Determination of desferoxamine and a major metabolite by high-performance liquid chromatography. Application to the treatment of aluminium-related disorders. (1985) (26)
- PROPERTIES AND CLASSIFICATION OF THE SOLUBLE ESTERASES OF HUMAN KIDNEY. (1964) (26)
- Induction of P-450 in workers exposed to dioxin. (1995) (26)
- Race and therapeutic drug response. (1989) (26)
- Metabolism of xenobiotics in different populations (1982) (25)
- Distribution of serum paraoxon hydrolyzing activities in a Canadian population. (1981) (25)
- Mephenytoin hydroxylase activity in human liver: inhibition by steroids. (1985) (25)
- Human hepatic cytochrome P450 2D6-like activity in nonhuman primates: catalytic characterization in vitro. (1993) (25)
- COMPARISONS OF TWO METHODS FOR TYPING OF SERUM CHOLINESTERASE AND PREVALENCE OF ITS VARIANTS IN A BRAZILIAN POPULATION. (1965) (24)
- Pharmacoanthropology: drug metabolism. (1984) (24)
- Studies on aromatic esterase and cholinesterase of human serum. (1959) (23)
- Distinctive patterns of amobarbital metabolites (1978) (22)
- Assays for CYP1A2 by testing in vivo metabolism of caffeine in humans. (1996) (21)
- Sparteine oxidation by the human liver: Absence of inhibition by mephenytoin (1984) (21)
- The interaction between cholinesterases and a series of local anesthetics. (1956) (21)
- Human metabolism of antipyrine labelled with 14C in the pyrazolone ring or in the N-methyl group. (1983) (20)
- Interethnic Differences in Drug Response (2005) (20)
- Amobarbital metabolism in man: N-glucoside formation. (1978) (20)
- HYPERRIGIDITY AND HYPERTHERMIA ASSOCIATED WITH ANESTHESIA (1968) (20)
- Caffeine biotransformation in human hepatocyte lines derived from normal liver tissue. (1994) (20)
- Pharmacogenomics: historical perspective and current status. (2005) (20)
- HYPERRIGIDITY AND HYPERTHERMIA ASSOCIATED WITH ANESTHESIA (1968) (20)
- Mephenytoin metabolism in vitro by human liver. (1985) (19)
- Catalytic and immunologic similarities between monkey and human liver cytochrome P-450db1 (human cytochrome P-450 2D6). (1992) (19)
- Urinary excretion of d-tubocurarine in man. (1953) (19)
- Variability in Response to Clozapine: Potential Role of Cytochrome P450 1A2 and the Dopamine D4 Receptor Gene (1999) (19)
- Inheritance of Malignant Hyperthermia—A Review of Published Data (1987) (19)
- Electrophoretic characterization of human dehydrogenases. (1965) (19)
- Serum cholinesterase levels in families and twins. (1963) (18)
- In vitro studies of human liver alcohol dehydrogenase variants using a variety of substrates. (1989) (18)
- Inhibitors of aromatic esterase of human serum. (1960) (18)
- Atypical plasma cholinesterase. A personal discovery story: a tale of three cities (2004) (17)
- Biliary excretion of diazepam in the rat. (1974) (17)
- THE INFLUENCE OF PH ON THE HYDROLYSIS OF BENZOYLCHOLINE BY PSEUDOCHOLINESTERASE OF HUMAN PLASMA. (1964) (17)
- Desferrioxamine for Alzheimer's disease (1991) (17)
- Pharmacogenetics in perspective. (2001) (16)
- Succinylcholine and malignant hyperthermia. (1972) (16)
- Interaction between aromatic esterase of human serum and bivalent metal ions. (1962) (16)
- Method to determine the enantiomers of ibuprofen from human urine by high-performance liquid chromatography. (1988) (16)
- Homogeneous murine myeloma protein-315 and spin-labeled DNP as a model system for spin-labeled hapten titration technique and spin immunoassay. (1973) (15)
- Genetic variation in the human hepatic cytochrome P-450 system (2004) (15)
- Effects of halothane and methoxyflurane on rat skeletal muscle mitochondria. (1972) (15)
- N-Hydroxylation of pentobarbital in man. (1977) (15)
- Poisoning with organophosphorus insecticides. (1965) (15)
- Effect of cold on rats chronically exposed to malathion. (1962) (15)
- Diazepam metabolism by rat and human liver in vitro: inhibition by mephenytoin. (1992) (15)
- A clinical and laboratory evaluation of four fluothane vaporizers (1958) (14)
- Interindividual variation in the enzymatic 15-keto-reduction of 13,14-dihydro-15-keto-prostaglandin E1 in human liver and in human erythrocytes (1997) (14)
- Seasonal variation of aryl hydrocarbon hydroxylase inducibility in human lymphocytes in culture. (1978) (14)
- Sparteine metabolism capacity in human liver: structural variants of human P450IID6 as assessed by immunochemistry. (1990) (14)
- Drugs causing rigidity in malignant hyperthermia. (1973) (14)
- Perspectives in pharmacogenetics. (2001) (14)
- Genetic factors in hepatic drug oxidation. (1976) (13)
- Pharmacoanthropology: outline, problems, and the nature of case histories. (1984) (13)
- Existence of phospholipid bilayer structure in the inner membrane of mitochondria. (1972) (13)
- Life of a pharmacologist or the rich life of a poor metabolizer. (1995) (12)
- Detailed characterization of experimentally derived human hepatic CYP1A1 activity and expression using differential inhibition of ethoxyresorufin O-deethylation by fluvoxamine (2001) (12)
- Paraoxonase phenotype distribution in Canadian Indian and Inuit populations. (1983) (12)
- THE EFFECTS OF SIALIDASE ON PSEUDOCHOLINESTERASE TYPES (1963) (11)
- [Pharmacogenetic problems in anesthesia]. (1966) (11)
- Spectrophotometric determination of fluothane vapour (1957) (11)
- PHARMACOGENETICS IN ANIMALS AND MAN (1968) (11)
- GENETIC DIFFERENCES IN DRUG METABOLISM (1963) (11)
- Stability of the paraoxonase phenotyping ratio in collections of human sera with differing storage times. (1983) (11)
- Determination of phenobarbital, p-hydroxyphenobarbital and phenobarbital-N-glucoside in urine by gas chromatography chemical ionization mass spectrometry. (1984) (11)
- Determination of low levels of amobarbital in serum by gas-liquid chromatography. (1972) (10)
- The fate of orally administered [4-14C]phenytoin in two healthy male volunteers. (1983) (10)
- Genetic aspects of drug safety. (1966) (10)
- KINETIC STUDIES ON THE HYDROLYSIS OF BENZOYLCHOLINE BY HUMAN SERUM CHOLINESTERASE (1956) (10)
- Amobarbital metabolism in man. Determination of N-hydroxyamobarbital and 3'-hydroxyamobarbital in urine by gas chromatography chemical ionization mass spectrometry. (1977) (10)
- Simultaneous determination of antipyrine, 4-hydroxyantipyrine, 3-hydroxymethylantipyrine and norantipyrine in urine by gas chromatography chemical ionization mass spectrometry. (1982) (10)
- Myotonia Associated With Small Cell Carcinoma of the Lung (1976) (10)
- Carbonyl (phenone) reductase in human liver: inter-individual variability. (1993) (10)
- Historical Aspects of Pharmacogenetics (2005) (9)
- Pharmacogenetics of caffeine and caffeine-halothane contractures in biopsies of human skeletal muscle. (1991) (9)
- A method for measuring glutethimide (Doriden) in human serum after intake of therapeutic doses. (1972) (8)
- Carbonyl (phenone) reductase in human liver: structure-activity relationship among substrates. (1992) (8)
- Genetic polymorphism in drug oxidation. (1989) (8)
- High-performance liquid chromatographic analysis of desferrioxamine. Pharmacokinetic and metabolic studies. (1988) (8)
- Abnormal Isoenzyme Patterns in Human Myopathies (1966) (8)
- Ethnic differences in reactions to drugs and xenobiotics : proceedings of a meeting held in Titisee, Black Forest, Federal Republic of Germany, October 3-6, 1985 supported by the Boehringer Ingelheim Fonds (1986) (8)
- Species differences of amobarbital metabolism: dihydroxyamobarbital formation. (1980) (7)
- The Pennsylvania State University College of Medicine 1990 Bernard B. Brodie Lecture. Pharmacogenetics: past and future. (1990) (7)
- Part I. Drug Metabolism Enzymes (1968) (7)
- ACTION OF ORGANOPHOSPHORUS COMPOUNDS UPON ESTERASES OF HUMAN LIVER (1963) (7)
- A pharmacogeneticist’s look at drug effects and the drug development process: an overview (2005) (7)
- Soluble esterases of human lung. (1970) (7)
- The occurrence of two hepatic microsomal sites for amobarbital hydroxylation. (1983) (7)
- Uptake and metabolism of diphenylhydantoin in the isolated perfused rat liver. (1978) (7)
- PHARMACOLOGY AND BIOLOGICAL VARIATION * (1966) (7)
- Pharmacogenetic variability in brain and muscle. (1994) (7)
- A sensitive method for determination of cytochrome P4502D6 activity in vitro using bupranolol as substrate. (1996) (7)
- Antipyrine metabolites in two populations. (1981) (7)
- Experiments with animals on the combined action of procaine and barbiturates (1955) (6)
- DOSE‐RESPONSE RELATIONSHIPS AND GENETIC VARIATION (1965) (6)
- Ethnic differences in reactions to drugs and xenobiotics. Caffeine and other drugs. (1986) (6)
- Multigenic traits and risk assessment in pharmacology: a population approach (2001) (6)
- Oxazepam as a probe of hepatic metabolism in patients with Alzheimer's disease (1988) (6)
- Variation in amobarbital metabolism: Evaluation of a simplified population study (1983) (6)
- Pharmacogenetic Investigation of Amobarbital Disposition (1979) (6)
- N-Glucosidation of amobarbital in the cat. (1985) (6)
- Unusual responses to drugs in some hereditary conditions (1961) (6)
- Paroxetine potentiates CNS side‐effects of perphenazine (1996) (5)
- Both populations and individuals are evolutionary targets: pharmacogenomic and cultural indicators (2002) (5)
- CYP1A2 Activity Predicts The Clozapine Steady‐State Concentration in Schizophrenic Patients (1999) (4)
- Synthesis of spin labelled 2,4-dinitrophenols and their activities in the uncoupling of oxidative phosphorylation in rat liver mitochondria. (1972) (4)
- Comparative drug elimination in man — Diphenylhydantoin and amobarbital (1975) (4)
- THE PLASMA CHOLINESTRASE: A NEW PRESPECTIVE (1981) (4)
- [The development of pharmacogenetics--a retrospective on the 75th birthday of Hans Herken]. (1988) (4)
- Some aspects of the pharmacology of nicotine. (1962) (4)
- Pharmacogenetic research: a revolutionary science. (1999) (4)
- Medical practice, race, and drug use. (2003) (4)
- Pharmacogenomics, Second Edition (2005) (4)
- International Symposium on Pharmacogenetics (1970) (4)
- Comparison of Effects of Several Inhalation Anaesthetics on Caffeine Induced Contractures of Normal and Malignant Hyperthermic Skeletal Muscle (1980) (4)
- INDIVIDUAL VARIATION IN DRUG METABOLISM AS CAUSE OF DRUG TOXICITY (1965) (4)
- Identification of p(4')-hydroxyantipyrine as a metabolite of antipyrine in man. (1981) (3)
- Personalized Medicine: Some Thoughts (2007) (3)
- Implications of Psychopharmacogenetics Research (1975) (3)
- I. Drug metabolism enzymes. Pharmacogenetics in animals and man. (1968) (3)
- A simple test for acetylator phenotype using caffeine. 1984. (2004) (3)
- [Butyrylcholine esterase in the blood serum of man and animal]. (1952) (3)
- 375 Esterase Action (1961) (2)
- Correspondence re: S. H. McQuilkin et al., analysis of within-subject variation of caffeine metabolism when used to determine cytochrome P4501A2 and N-Acetyltransferase-2 activities. Cancer Epidemiol., Biomarkers & Prev., 4: 139-146, 1995. (1996) (2)
- Multivariate cluster analysis of a human hepatic cytochrome P450 database (2002) (2)
- Some aspects of thyroid function in rats after feeding of levomepromazine. (1960) (2)
- The relation of plasma cholinesterases to response to clinical doses of succinylcholine (2008) (2)
- Genetic factors in adverse drug reactions. (1971) (2)
- Pharmacogenetics: Its Place in Medicine and Biology (1992) (2)
- Pharmacogenetics and the Predictability of Drug Responses (2008) (2)
- Ethnic differences in reactions to drugs and xenobiotics. Conjugation reactions. (1986) (1)
- Assets and limitations of animal models. (1978) (1)
- High affinity of quinidine for a stereoselective microsomal binding site as determined by a radioreceptor assay (1984) (1)
- Book Review The Relevance of Ethnic Factors in the Clinical Evaluation of Medicines (CMR Workshop Series.) Edited by Stuart Walker. 262 pp. Boston, Kluwer Academic, 1994. $85. 0-7923-8843-7 (1995) (1)
- An A-Z Guide to Pharmacogenomics. (2007) (1)
- 124 – GENETIC AND KINETIC STUDIES OF THE FATE OF AMOBARBITAL IN MAN (1977) (1)
- Metabolism of 14C-iodochlorhydroxyquin in the dog and the rat. (1984) (1)
- Rigidity and malignant hyperthermia associated with anaesthesia (2004) (1)
- Morphine adaptation, hexobarbital, alcoholism general remarks (2004) (1)
- The relation of plasma cholinesterases to response to clinical doses of succinylcholine (1956) (1)
- An assessment of short-cut procedures for studying drug metabolism in vivo using amobarbital as a model drug (2004) (1)
- How Genetic Factors Affect Individual Drug Responses (1967) (1)
- Interactions of bupranolol with the polymorphic debrisoquine/sparteine monooxygenase (CYP2D6) (2004) (1)
- CHROMATOGRAPHIC SEPARATION OF SUCCINYLCHOLINE AND ITS HYDROLYSIS PRODUCTS. (1963) (1)
- Metabolism of psychoactive drugs (1982) (1)
- Report on the workshop “molecular basis of polymorphic drug oxidation in man”, Otzenhausen, 1983 (1984) (1)
- Effects of Enzymes on the Pharmacology of Isolated Organs (1968) (0)
- Drug therapies as sources of information about alcoholism. (1987) (0)
- Utilizing urinary metabolite data in studying the variability of acetaminophen metabolism. (1993) (0)
- General Conclusions and Future Directions (2005) (0)
- Letters to the editor: the tragic death of Dr. Hugh Orr Cameron. (1969) (0)
- Pharmacogenetics and Pharmacogenomics: An Overview (2005) (0)
- Pharmacogenetics of psychotropic drugs. By Bernard Lerer, editor. Cambridge University Press, Cambridge, New York, Port Melbourne, Madrid, Capetown, 2002 (2005) (0)
- 548 – PHARMACOGENETIC INVESTIGATIONS OF AMOBARBITAL DISPOSITION (1978) (0)
- Cytochrome p45 0IID6 (debrisoquine hydroxylase): inhibition studies in liver and brain (1990) (0)
- Inhibition ofhumancytochrome P4502D6(CYP2D6) by methadone (1993) (0)
- Lessons from pharmacogenetics (1991) (0)
- [Photometric determination of enzymic novocain hydrolysis]. (1951) (0)
- Genetic Aspects of Drug Development (2013) (0)
- Obituary: George Herbert William Lucas, Ph.D. (1974) (0)
- [Choleresis induced by synthetic drugs. 4. Poikilothermic study of the anesthetized rat]. (1950) (0)
- Ethnic differences in reactions to drugs and xenobiotics. Outlook of a pharmacologist. (1986) (0)
- 2862 – ANTIPYRINE AS A PROBE FOR THE MULTIPLICITY OF HEPATIC MONOOXYGENASES IN MAN (1978) (0)
- Phannacogeoetks: heredity and the response to drags. (1962) (0)
- Vol. 58, 1999 (1999) (0)
- Contributing authors (2005) (0)
- [Not Available]. (1949) (0)
- Editorial help (2004) (0)
- Reply (1991) (0)
- Referees for volume 32 (2022) (0)
- Search for single gene effects in multifactorial inheritance in pharmacogenetics. (1978) (0)
- IDENTITY OF DEBRISOQUINE/SPARTEINE MONOOXYGENASE (1985) (0)
- Symposium Genetic Factors Influencing Drug Action (1983) (0)
- Malignant hyperthermia, then and now (1984) (0)
- Malignant hyperthermia: an investigation of five patients. (1973) (0)
- Re: 'Developmental progress in very low birth weight infants during the first year of life'. (1987) (0)
- Genetic Variation in the Hepatic Cytochrome P-450 System (1987) (0)
- EFFECT OF COLD ON RATS CHRONICALLY EXPOSED TO MALATHION (1962) (0)
- INDUCTION OF ARYL HYDROCARBON HYDROXYLASE (AHH) FORMS OF CYTOCHROME P-450 CAN BE MONITORED BY CAFFEINE URINARY METABOLITE RATIOS (1987) (0)
- Genetic causes of interindividual and interethnic differences in drug metabolism (1992) (0)
- [Nitrate esters of pentaerythrite]. (1950) (0)
- [Not Available]. (1949) (0)
- CONCLUDING REMARKS (1968) (0)
- Sparteine monooxygenase in brain and liver: Identified by the dopamine uptake blocker ( sup 3 H)GBR-12935 (1990) (0)
- Choleresis by synthetic means; quantitative and qualitative effect of phenylmethylcarbinol in the rat. (1949) (0)
- Letter: Myotonia associated with small cell carcinoma of the lung. (1976) (0)
- Subject Index Vol. 58, 1999 (1999) (0)
- Letters to the editor (1969) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Werner Kalow?
Werner Kalow is affiliated with the following schools:
